14th International Conference on Complement Therapeutics


Important: The program online is copyrighted to each author and should not be copied and pasted!
  • Code of conduct

    Aegean Conferences is committed to making its meetings an inclusive space for sharing ideas and knowledge. The code of conduct can be found at:https://www.aegeanconferences.org/src/App/pages/view/AegeanCodeofConduct 


    Accommodations for the conference are at the Sheraton Hotel. The Hotel is located in Ixia, Rhodes, 14.5 km from the airport.

    Arrival and Check-in 

    Attendees are expected to arrive/check-in after 3:00 PM local time. Registered participants arriving after 10:00 PM should make alternative dinner arrangements.  

    Conference Venue

    The Sheraton Conference Center is located at the hotel.  

    Handicapped Accessibility 

    The site is fully handicapped accessible. 

    Oral Presentations

    Speakers are asked to bring their USB flash drive to the reception desk at least 30 minutes prior to the session. The allocated time for all presentations, unless otherwise indicated, includes five minutes Q&A. 

    City Tour

    Buses for the city tour will depart from the hotel front lobby 3:00 PM. Badges are required for participation. 


    Breakfast for registered participants and registered accompanying persons will be served at the Sheraton Hotel main restaurant during the hours scheduled in this program.

    Lunches/Informal Discussions

    Lunches for registered participants and registered accompanying persons will be served during the times indicated in this program at the main restaurant. Badges are required for admission.

    Dinners/Informal Discussions

    Three of the dinners/informal discussions will be served during the times indicated in the program. Vegetarian entrees are available only upon request in advance of the meeting. 

    Internet, Phone, & Computer 

    Wireless internet access is available throughout the conference center free of charge during meeting hours. 

    Certificate of Participation

    A Certificate of Participation will be distributed to a participant for those sessions that the participant has attended. A participant must attend an entire session to receive credit for that particular session. Late arrivals and early departures from a session will preclude a participant from receiving credit for that session.

    Meeting Room Policy

    Mask Recommendation

    Face masks are recommended indoors.

    No Photographs and Recording Devices 

    Participants are not allowed to photograph and/or record using cameras, mobile telephones and other recording devices during the slide and poster presentations. 

    Other Information

    Animals are not permitted on site. 

    Badges are required for admission to all events. 

    All Aegean Conferences events are non-smoking. 


    Aegean Conferences expects attendees to conform their conduct at these meetings to the policies and procedures of their employing institution or company. If we learn of improper conduct by an attendee, we will take appropriate action, including reporting such conduct to the attendee's employing institution or company and barring the attendee from participation in our meetings.

    The Aegean Conferences is committed to protecting the privacy of its visitors. Information that our meeting participants provide or that is derived from internal website tracking is not sold, rented or shared with any individual or organization.  You can let us know that you would prefer not to receive information by e-mail at any time, simply by sending an e-mail to unsubscribe@aegeanconferences.org. If you do so, we will not use your personal information for informing you on our future meetings and other services. 

Friday, June 17

06:00 PM - 07:00 PM
Conference Registration
07:00 PM - 10:00 PM
Welcome Reception and Dinner

Saturday, June 18

08:00 AM - 08:50 AM
08:50 AM - 09:00 AM
Welcome and Opening Remarks - John D. Lambris
Therapeutic complement modulation in severe COVID-19
Chairs: Carl Atkinson and Lisa Gralinski
09:00 AM - 09:20 AM
Targeting complement in COVID-19: where we stand and what lies ahead
Dimitrios C. Mastellos1, Panagiotis Skendros2, Markus Huber-Lang3, Bo Nilsson4, Antonio M. Risitano5, Konstantinos Ritis2, Despina Yancopoulou6, and John D. Lambris7
09:20 AM - 09:40 AM
Regulation of Inflammation by local complement in COVID-19
Ben Afzali
09:40 AM - 10:00 AM
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
Cecilia Garlanda
10:00 AM - 10:20 AM
Complement signaling mediates coronavirus-induced lung injury
Lisa E Gralinski, Ande West, Sarah R Leist, and Ralph S Baric
10:20 AM - 10:35 AM
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Matteo Stravalaci1, Niloufar Kavian-Tesslar1, Isabel Pagani2, Hang Zong1, Francesco Scavello1, Barbara Bottazzi1, Elisa Vicenzi2, Alberto Mantovani1,3,4, and Cecilia Garlanda1,3
10:35 AM - 10:50 AM
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Michael Hultström2,8,9,10, Robert Frithiof2, Jonathan Grip3,11, Linnea Lindelöf1, Olav Rooijackers3,11, Sara Pigazzini4, Mari Niemi4, Mattia Cordioli4, Lindo Nkambule4, Tomislav Maricic5, Kristina Nilsson Ekdahl1,12, Bo Nilsson1, Miklós Lipcsey2,7, Hugo Zeberg5,6, and Oskar Eriksson1
10:50 AM - 11:30 AM
Coffee Break and Poster Viewing
Therapeutic development: novel complement inhibitors
Chairs: Cecilia Garlanda and Antonio Risitano
11:30 AM - 11:50 AM
Taking C3 inhibition to the next level: new insights and clinical opportunities
John D Lambris
11:50 AM - 12:10 PM
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Antonio M Risitano1,3,4, Regis Peffault de Latour4,5, Luana Marano1, Camilla Frieri1,3,5, Despina Yancopoulou6, Dimitrios C Mastellos7, and John D Lambris
12:10 PM - 12:25 PM
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Alexander McQuiston1, Changhai Li1, Zhenxiao Tu1, Kunal Patel2, Logan Langerude1, Stephen Tomlinson3, and Carl Atkinson1
12:25 PM - 12:40 PM
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
Said Rabbani1, Rachel Hevey1, Martin Smiesko1, Daniel Ricklin1, and Roman Peter Jacob2
12:40 PM - 12:55 PM
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Anjan K Bongoni3, Ingela B Vikstrom1, Jennifer L McRae3, Evelyn J Salvaris3, Nella Fisicaro3, Martin J Pearse1, Sandra Wymann2, Tony Rowe1, Adriana Bazmorelli1, Peter J Cowan3, and Matthew P Hardy1
12:55 PM - 01:10 PM
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Thomas E Cox1, Helena Thomas Eke1, Jan K Jensen2, Thomas M Hallam1, Shyam R Iyer3, James McGuire3, and Kevin J Marchbank1
01:10 PM - 01:25 PM
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Cedric S Cui1, Vinod Kumar1, Xaria X Li1, Ning Liu1, Richard J Clark1, Andrew K Whittaker2, Felicity Y Han2, John D Lee1, and Trent M Woodruff1
01:25 PM - 03:00 PM
Lunch and Informal Discussions
03:00 PM - 07:15 PM
Informal Discussions
07:15 PM - 10:30 PM
Dinner and Informal Discussions

Sunday, June 19

08:00 AM - 09:00 AM
Structural insights and mechanisms of activation, regulation and signaling crosstalk
Chairs: Brian Geisbrecht and Veronique Fremeaux-Bacchi
09:00 AM - 09:20 AM
Structural insights into complement protease complexes
Piet Gros
09:20 AM - 09:40 AM
Modified DNA aptamers as inhibitors of complement proteins and their complexes
Brian V Geisbrecht
09:40 AM - 10:00 AM
Activation of the complement system by cholesterol crystals
Terje Espevik1, Nathalie Niyonzima1, Claudia Kemper2, Bente E. Halvorsen3, and Tom E. Mollnes4,5
10:00 AM - 10:15 AM
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
Henry Nording1, Antje Luebken1, Tobias Geisler2, and Harald Langer1
10:15 AM - 10:30 AM
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Alexandra Gerogianni 1, Jordan D Dimitrov2, Victoria Poillerat 2, Satheesh Chonat 3, Kerstin Sandholm 1, Karin E McAdam4, Kristina N Ekdahl 5, Tom E Mollnes4, Camilla Mohlin 1, Lubka T Roumenina 2, and Per H. Nilsson 1
10:30 AM - 10:45 AM
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
Henri Wedekind1, Arno Fenske1, Andreas Tiede2, Birgit Weinhold1, Anja Münster-Kühnel1, and Markus Abeln1
10:45 AM - 11:05 AM
The intertwined relationship between complement and platelet activation
Harald Langer
11:05 AM - 11:45 AM
Coffee Break and Poster Viewing
Complement in cancer: mechanistic insights and therapeutic concepts
Chairs: Ruben Pio and Lubka Roumenina
11:45 AM - 12:05 PM
Complement-related therapies to treat cancer: where to target?
Ruben Pio
12:05 PM - 12:25 PM
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
Ronald P Taylor1, Margaret A Lindorfer1, Adrian Wiestner1, Erika M Gaglione2, Sivasubramanian Baskar2, Christoph Rader3, and Haiyong Peng3
12:25 PM - 12:40 PM
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Callum Beach1, Dominika Majorova 1, David MacLean1, Stavros Melemenidis 3, Mahnaz Damavandi Darvish 4, Dhanya K. Nambiar3, Ryan K. Kim3, Kerriann M. Casey6, Yanyan Jiang1, Eui Jung Moon1, Dadi Jiang, Albert C. Koong , Simon Buczacki 4, Tim Maughan1, Simon Leedham 2, Edward G. Graves 3, Quynh-Thu Le3, Trent M. Woodruff 7, Manuel Stucki 8, Amato J. Giaccia1, and Monica M. Olcina1
12:40 PM - 12:55 PM
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Margot Revel, Marie Daugan, Marie-Agnès Dragon-Durey, Catherine Sautes-Fridman, Wolf-Herve Fridman, and Lubka Roumenina
12:55 PM - 01:10 PM
Intracellular activation and regulation of the complosome – driver of cancer progression
Alessandra Zarantonello, Margot Revel, Tania Robe-Rybkine, Antonin Bourdin, Catherine Sautes-Fridman, Wolf Herman Fridman, and Lubka T Roumenina
01:10 PM - 01:30 PM
Complementome as a driver of (tumor) cell fate
Lubka Roumenina
01:30 PM - 03:00 PM
Lunch and Informal Discussions
03:00 PM - 07:30 PM
Informal Discussions
07:30 PM - 10:30 PM
Dinner and Informal Discussions

Monday, June 20

08:00 AM - 09:00 AM
Complement in neuroinflammation and neurodegenerative diseases
Chairs: Cynthia Ann Lemere and Paul Morgan
09:00 AM - 09:20 AM
Targeting complement for therapy of neurodegenerative diseases.
Paul B Morgan
09:20 AM - 09:40 AM
Global C3 lowering in adult mice protects against hippocampal aging
Andre F Batista1,2, Esra Yalcin3,4, Maren K Schroeder1, Khyrul Khan1, Shaomin Li1,2, Michelle Mei1, Jessy Presumey3,4, Michael C Carroll3,4, and Cynthia A Lemere1,2
09:40 AM - 10:00 AM
The contribution of the terminal pathway to disease progression in neurological disorders
Frank Baas
10:00 AM - 10:15 AM
Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
Katherine Given1, Elizabeth Acker3, and Jeffrey L Bennett2
10:15 AM - 10:30 AM
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Inge Van de Walle1, Kevin Budding2, Lill Eva Johansen3, Kim Dijkxhoorn2, Elisabeth de Zeeuw2, Lauri M Bloemenkamp2,3,4, Domenica Gandini1, Olivier Van de Steen1, Jeanette H.W. Leusen2, Hans de Haard1, C. Erik Hack2, and W. Ludo van der Pol4
10:30 AM - 10:45 AM
Targeting novel anti-complement drugs to the brain for therapy of dementia.
Wioleta Milena Zelek1, Ryan J Bevan1, Maarten Dewilde2, Bart De Strooper3, and Bryan Paul Morgan1
10:45 AM - 11:30 AM
Coffee Break and Poster Viewing
Complement targeting in ocular inflammation and hemolytic disorders
Chairs: Gregory Hageman and Bärbel Rohrer
11:30 AM - 11:45 AM
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Gregory S Hageman, Chris M. Pappas, Jin Liu, Robert A. Amstadt, Brandi L. Williams, Nathan A. Seager, Jill L. Hageman, Karen Curtin, Moussa Zouache, and Burt T. Richards
11:45 AM - 12:00 PM
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Moussa A Zouache, Chris M Pappas, Robert A Anstadt, Jin Liu, Stacie Matthews, Jill L Hageman, Burt T Richards, and Gregory S. Hageman
12:00 PM - 12:15 PM
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Balasubramaniam Annamalai1, Nathaniel Parsons1, Crystal Nicholson1, Elisabeth Obert1, Bryan Jones3, and Bärbel Rohrer1,2
12:15 PM - 12:30 PM
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Claire L Harris, James Francis, Eva Pekle, Sonal Varsani, Emanuela Gardenal, Kate Carney, Anna Dreismann, Luisa Mendonca, Darin Curtiss, Nadia Waheed1,, and Jane Hughes
12:30 PM - 12:45 PM
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Anne Grunenwald, Julie Peliconi, Margot Revel, Julien Lavergne, Elodie Voilin, V Poillerat, and Lubka Roumenina
12:45 PM - 01:15 PM
Live poster session A: 5-min flash talks
01:05 PM - 03:30 PM
Lunch and Informal Discussions
03:30 PM - 07:30 PM
City Tour and Discussions
07:30 PM - 10:30 PM
Dinner and Informal Discussions

Tuesday, June 21

08:00 AM - 09:00 AM
Genetic drivers, mechanisms and targets in (auto)-immune and inflammatory diseases
Chairs: Georgios Hajishengallis and Monica Olcina
09:00 AM - 09:20 AM
Is therapeutic complement modulation beneficial after trauma?
Markus Huber-Lang1, Ludmila Lupu1, Marco Mannes1, Lisa Wohlgemuth1, John D Lambris2, and Tom E Mollnes3
09:20 AM - 09:40 AM
The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
Samyr Kenno1, Sina Borus1, Katja Bieber3, and Jörg Köhl1,
09:40 AM - 10:00 AM
Complement is required for microbe-driven induction of Th17 and periodontitis
Hui Wang1, Hidetaka Ideguchi1, Tetsuhiro Kajikawa1, Dimitrios C Mastellos3, John D Lambris2, and George Hajishengallis1
10:00 AM - 10:15 AM
Lest we forget: Lessons from complement reactions to oligos, anti drug antibodies and AAV gene therapy.
Ashley Frazer-Abel
10:15 AM - 10:35 AM
Targeted Panels or Exome – Which is the Right NGS Approach for complement-mediated diseases?
veronique Fremeaux-Bacchi
10:35 AM - 10:55 AM
Clinical Xenotransplantation: Implications for Complement Inhibition
Robert Montgomery
10:55 AM - 11:10 AM
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Jean Francis1, Hamza Hassan1, Josh Korzenik 2, Deepak Rao 2, Jennifer Ho3, David Salant 1, and John M Sloan 1
11:10 AM - 11:45 AM
Coffee Break and Poster Viewing
Complement: a multifaceted driver of thromboinflammation
Chairs: Markus Huber-Lang and Wioleta Zelek
11:45 AM - 12:05 PM
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Benjamin S Storm1,2,3,4, Judith K Ludviksen2, Dorte Christiansen2, Hilde Fure2, Kristin Pettersen2, Anne Landsem2, Bent A Nilsen1,4, Knut Dybwik1, Tonje Braaten4,5, Erik W Nielsen1,3,4,6, and Tom E Mollnes2,6,7,8,9
12:05 PM - 12:20 PM
Complement-induced prothrombotic activation of platelets requires the lysis of cells
Marco Mannes1, Veronika Pechtl2, Christoph Q Schmidt2, Susanne Hafner2, Vivek A Manivel3, Oskar Erkisson3, Kristina N Ekdahl3,4, Bo Nilsson3, John D Lambris5, and Markus Huber-Lang1
12:20 PM - 12:35 PM
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Hailey M Harris1, Sanjay Khandelwal2, Lubica Rauova3, John Lambris4, Douglas B Cines4, Brandon Garcia5, and Gowthami M Arepally2
12:35 PM - 12:50 PM
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Ole L. Brekke1,2, Joost Grond1,2, Anne Landsem1, Dorte Christiansen1, Judith A. Ludviksen1, Corinna Lau1, Trent Woodruff3, John D. Lambris4, Terje Espevik6, and Tom E. Mollnes1,2,5,6,7
12:50 PM - 01:05 PM
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Bo Nilsson, Alireza Biglarnia, Kristina N Ekdahl, Marianne Waern Jensen, and Yuji Teramura
01:10 PM - 01:40 PM
Live poster session B: 5-min flash talks
01:40 PM - 01:45 PM
Closing Remarks - John D. Lambris
01:45 PM - 03:00 PM
Lunch and Informal Discussions
03:00 PM - 08:00 PM
Informal Discussions
08:00 PM - 11:30 PM
Farewell Dinner

Wednesday, June 22

08:00 AM - 10:00 AM
10:00 AM - 12:00 PM